地舒单抗联合特立帕肽治疗对绝经后骨质疏松患者的影响  

Effect of Treatment with Denosumab Combined with Teriparatide on Patients with Postmenopausal Osteoporosis

作　　者：刘小红 廖飞勇 程中楷 郑火平 黄玉姬 LIU Xiaohong;LIAO Feiyong;CHENG Zhongkai;ZHENG Huoping;HUANG Yuji(Department of Endocrinology,the Third People's Hospital of Jingdezhen,Jingdezhen 333000,China;不详)

机构地区：[1]景德镇市第三人民医院内分泌科,江西景德镇333000 [2]景德镇市第三人民医院急诊外科创伤中心,江西景德镇333000 [3]景德镇市第三人民医院康复科,江西景德镇333000

出　　处：《中国医学创新》2024年第28期25-29,共5页Medical Innovation of China

摘　　要：目的:研究地舒单抗联合特立帕肽对绝经后骨质疏松患者骨代谢及血清骨硬化蛋白(SOST)、骨桥蛋白(OPN)的影响。方法:选择景德镇市第三人民医院2021年1月—2022年11月收治的80例绝经后骨质疏松患者,使用随机数字表法将患者分为对照组和观察组,各40例。对照组使用地舒单抗治疗,观察组使用地舒单抗联合特立帕肽治疗。对比两组治疗前后骨密度、骨代谢指标[骨钙素(OCN)、Ⅰ型胶原氨基端延长肽(PⅠNP)、β胶原降解产物(β-CTX)、骨碱性磷酸酶(BALP)]、性激素[雌二醇(E2)、促卵泡激素(FSH)、黄体生成素(LH)]、血清SOST、OPN水平。结果:治疗后,观察组腰椎、全髋、股骨颈骨密度均高于对照组,差异均有统计学意义(P<0.05);治疗后,观察组OCN、PⅠNP、β-CTX、BALP均低于对照组,差异均有统计学意义(P<0.05);治疗后,观察组E2高于对照组,LH、FSH均低于对照组,差异均有统计学意义(P<0.05);治疗后,观察组SOST、OPN均低于对照组,差异均有统计学意义(P<0.05)。结论:地舒单抗联合特立帕肽治疗绝经后骨质疏松患者能有效提高骨密度,改善骨代谢指标和性激素,降低血清SOST、OPN水平。Objective:To explore the effects of Denosumab combined with Teriparatide on bone metabolism,serum sclerostin(SOST)and osteopontin(OPN)in patients with postmenopausal osteoporosis.Method:A total of 80 patients with postmenopausal osteoporosis admitted to the Third People's Hospital of Jingdezhen from January 2021 to November 2022 were selected and divided into control group and observation group by random number table method,with 40 cases in each group.The control group was treated with Denosumab,and the observation group was treated with Denosumab combined with Teriparatide.Bone density(BMD),bone metabolism indexes[osteocalcin(OCN),procollagen typeⅠN-terminal propeptide(PⅠNP),β-collagen degradation product(β-CTX),bone alkaline phosphatase(BALP)],sex hormones[estradiol(E2),follicle stimulating hormone(FSH),luteinizing hormone(LH)],serum SOST,OPN levels before and after treatment of two groups were compared.Result:After treatment,the bone density of lumbar spine,total hip and femoral neck in observation group were higher than those in control group,the differences were statistically significant(P<0.05).After treatment,OCN,PⅠNP,β-CTX and BALP in observation group were lower than those in control group,the differences were statistically significant(P<0.05).After treatment,E2 in observation group was higher than that in control group,LH and FSH were lower than those in control group,the differences were statistically significant(P<0.05).After treatment,SOST and OPN in observation group were lower than those in control group,the differences were statistically significant(P<0.05).Conclusion:Denosumab combined with Teriparatide in the treatment of patients with postmenopausal osteoporosis can effectively increase bone density,improve bone metabolism indexes and sex hormones,and reduce serum SOST and OPN levels.

关 键 词：地舒单抗 特立帕肽 绝经后骨质疏松 骨代谢 

分 类 号：R580[医药卫生—内分泌]